Abstract: A light-emitting device comprises a first semiconductor layer and a semiconductor mesa formed on the first semiconductor layer, wherein the first semiconductor layer comprises a first sidewall and a first semiconductor layer first surface surrounding the semiconductor mesa, and the semiconductor mesa comprises a second sidewall; and a first reflective structure comprising a first reflective portion covering the first sidewall and a second reflective portion covering the second sidewall, wherein the first reflective portion and the second reflective portion are connected to form a first reflective structure outer opening to expose the first semiconductor layer first surface in a top view of the light-emitting device.

Abstract: An optical device is provided. The optical device includes a ring waveguide and a bus waveguide. The ring waveguide includes a coupling region. The bus waveguide is disposed adjacent to and spaced apart from the coupling region of the ring waveguide. The bus waveguide includes a coupling structure corresponding to the coupling region.

Abstract: Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Abstract: Disclosed is a manufacture method of the array substrate, including: sequentially forming a gate, a gate insulating layer, an active layer, an ohmic contact layer and a metal layer on a substrate, forming a photoetching mask on the metal layer, where thickness of the photoetching mask in a half exposure area of the mask plate is from 2000 ? to 6000 ?; etching the metal layer, the ohmic contact layer and the active layer outside a covering area of the photoetching mask; ashing the photoetching mask for a preset time with an ashing reactant, wherein the ashing reactant comprises oxygen, and the preset time is from 70 seconds to 100 seconds; and sequentially etching the metal layer, the ohmic contact layer and the active layer based on the ashed photoetching mask, and forming a channel region of the array substrate. The present disclosure further discloses an array substrate, and a display panel.

Abstract: Provided is a method for classifying diseases using artificial intelligence (AI) of an electronic apparatus. The method for classifying diseases may comprise obtaining auscultation sound data and auscultation position data, obtaining feature information based on the auscultation sound data and obtaining auscultation position information based on the auscultation position data, generating combined information by combining the feature information and the auscultation position information, and identifying at least one of disease information corresponding to the combined information, by using an AI model.

Abstract: An electronic device includes a display panel, a first optical part, and a second optical part including a diffraction optical element having a diffraction grating. The display panel include a first display area for displaying a first image having a first color, a second display area disposed adjacent to the first display area to display a second image having a second color different from the first color, and a third display area disposed adjacent to the second display area to display a third image having a third color different from the first color and the second color.

Abstract: An organic light emitting display apparatus including a substrate including a plurality of pixel areas; a pixel electrode on the substrate; an opposite electrode on the pixel electrode, the opposite electrode transmitting light; an organic light emitting layer between the pixel electrode and the opposite electrode, the organic light emitting layer emitting a first light toward the opposite electrode; a light emitting layer on the opposite electrode, the light emitting layer absorbing a portion of the first light and emitting a second light; and a sealing layer on the light emitting layer, the sealing layer sealing the pixel electrode, the opposite electrode, the organic light emitting layer, and the light emitting layer.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a transmitter may detect at least one distance between the transmitter and a receiver. The transmitter may transmit, to the receiver, information using a selected band of a wide band or a narrow band, where the selected band is based at least in part on the at least one distance. Similarly, in some aspects, a receiver may detect at least one distance between the receiver and a transmitter. The receiver may receive, from the transmitter, information using a selected band of a wide band or a narrow band, where the selected band is based at least in part on the at least one distance. Numerous other aspects are described.

Abstract: A method for assessing drug-resistant Klebsiella pneumoniae includes the following steps. A test sample is provided, wherein the test sample includes a Klebsiella pneumoniae. A spectrum analysis step is performed, wherein the test sample is detected by a mass spectrometry method so as to obtain a target mass spectrum data. An assessing step for drug-resistant Klebsiella pneumoniae is performed, wherein the target mass spectrum data is analyzed so as to assess whether the Klebsiella pneumoniae is resistant to a carbapenem antibiotic or a colistin or not. When the Klebsiella pneumoniae is resistant to the carbapenem antibiotic, the target mass spectrum data includes a first anti-carbapenem feature mark, and when the Klebsiella pneumoniae is resistant to the colistin, the target mass spectrum data includes a first anti-colistin feature mark.

Abstract: An example implantable medical device includes a stimulating lead includes receive one or more signals indicative of one or more physiologic parameters; deliver electrical therapy to stimulate a muscle wrapped around a heart via one or more electrodes of a stimulating lead; and adjust an amount of the electrical therapy delivered, via the stimulating electrodes, based on the one or more physiologic parameters.

Abstract: Provided is a method for classifying diseases using artificial intelligence (AI) of an electronic apparatus. The method for classifying diseases may comprise obtaining auscultation sound data and auscultation position data, obtaining feature information based on the auscultation sound data and obtaining auscultation position information based on the auscultation position data, generating combined information by combining the feature information and the auscultation position information, and identifying at least one of disease information corresponding to the combined information, by using an AI model.

Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.

Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.

Abstract: A method for producing exosomes in a large-scale by using a cyclic tensile bioreactor to stimulate cells to release exosomes. In addition, the exosome having an anti-HLA-G protein specific for cancer is used as a delivery vehicle to deliver therapeutic agents for treating cancer.

Abstract: The present disclosure provides an anti-immune-checkpoint nanobody that specifically binds to a programmed cell death ligand 1. The present disclosure also provides the nucleic acid sequence of the anti-immune-checkpoint nanobody, use of the anti-immune-checkpoint nanobody for treating cancer and immune-related disorders, and a method for detecting expression levels of PD-L1.

Abstract: A multispecific nanobodies chimeric antigen receptor and T-cell engager includes an HLA-G nanobody chimeric antigen receptor and a bispecific T-cell engager. The HLA-G nanobody chimeric antigen receptor includes an HLA-G nanobodies unit, a transmembrane domain, and a CD3z signaling domain. The bispecific T-cell engager includes a PD-L1 nanobodies unit and a CD3e nanobody.

Abstract: The present disclosure relates to a chimeric antigen receptor, a nucleic acid, a chimeric antigen receptor expression plasmid, a chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the chimeric antigen receptor expressing cell. The chimeric antigen receptor is specific to human leukocyte antigen G. The nucleic acid encodes the chimeric antigen receptor. The chimeric antigen receptor expression plasmid expresses the chimeric antigen receptor. The chimeric antigen receptor expressing cell is obtained by transducing the chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.

Abstract: Present invention is related to a tumor microenvironment on chip or a biochip for cell therapy having a carrier, a first cell or tissue culture area and a second cell or tissue area imbedded within the carrier. The present invention provides a biochip successfully cooperating micro fluidic technology and cell culture achieving the goal for detecting or testing the function of cell therapy for cancer or tumor.

Abstract: An artificial intelligence assisted medical diagnosis method for a sepsis is proposed. A database reading step is performed to read a sepsis database and at least one database to be tested of a storing unit. The sepsis database includes a plurality of sepsis data, and the at least one database to be tested includes a plurality of data to be tested. A data table creating step is performed to create a sepsis data table according to the sepsis data, and create a data table to be tested according to the data to be tested. A model training step is performed to train the sepsis data table according to a K-fold cross-validation and a machine learning algorithm to generate a sepsis diagnosis model. A sepsis predicting step is performed to input the data table to be tested into the sepsis diagnosis model to calculate a sepsis prediction result.